---
document_datetime: 2024-12-12 10:51:11
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/isturisa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: isturisa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.8340257
conversion_datetime: 2025-12-24 14:39:42.91044
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Isturisa

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0024/G          | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - | 10/12/2024                          |                                             | SmPC, Annex II, Labelling and PL |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |             |                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10820 /202401 | Periodic Safety Update EU Single assessment - osilodrostat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 19/09/2024 | 18/11/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10820/202401. |
| IB/0023             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/10/2024 | n/a        |             |                                                                                                                                            |
| R/0022              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/07/2024 | 07/10/2024 | SmPC and PL |                                                                                                                                            |
| IA/0020/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 19/03/2024 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0017/G | This was an application for a group of variations. Grouped application comprising two type II variations (C.I.4) as follows: - Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study LINC4 (study CLCI699C2302 - A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing's disease). - Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study LINC3 (study CLCI699C2301 - A Phase III, multi-center, double- blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease). The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to introduce some minor | 07/03/2024 | 28/06/2024 | SmPC and PL | Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from studies LINC4 and LINC3. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                        |            |            |             |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IAIN/0019           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                         | 22/12/2023 | n/a        |             |                                   |
| IA/0018/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 04/12/2023 | n/a        |             |                                   |
| PSUSA/10820 /202301 | Periodic Safety Update EU Single assessment - osilodrostat                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/08/2023 | n/a        |             | PRAC Recommendation - maintenance |
| IA/0016             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                              | 24/07/2023 | n/a        |             |                                   |
| IB/0015/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 27/06/2023 | 28/06/2024 | SmPC, Annex |                                   |

<div style=\"page-break-after: always\"></div>

| B.II.b.2.c.2 - Change to arrangements and quality Including batch control/testing B.II.b.1.e - Replacement manufacturing site for the manufacturing operation(s) release, batch control, primary packaging, for non-sterile B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.b.4.b - Change in the size ranges) of the finished down to 10-fold B.II.b.4.b - Change in the size ranges) of the finished down to 10-fold B.II.a.1.a - Change or addition or other markings including of inks used for product imprints, bossing or other B.II.e.2.a - Change in the and/or limits of the immediate finished product - Tightening B.II.c.2.b - Change in test - Deletion of a test procedure procedure is already authorised B.II.c.2.b - Change in test - Deletion of a test procedure procedure is already authorised B.II.c.2.b - Change in test   | II and PL   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|

<div style=\"page-break-after: always\"></div>

|                     | procedure is already authorised B.II.c.2.b - Change in test procedure for an excipient - Deletion of a test procedure if an alternative test procedure is already authorised A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                              |            |            |             |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0013             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                           | 15/12/2022 | n/a        |             |                                                                                                                                            |
| IA/0012             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                        | 15/12/2022 | n/a        |             |                                                                                                                                            |
| PSUSA/10820 /202201 | Periodic Safety Update EU Single assessment - osilodrostat                                                                                                                                                                                                                                                                                                                                                                                              | 15/09/2022 | 09/11/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10820/202201. |
| IA/0010/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.a - Change to importer, batch release | 22/03/2022 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                    |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10820 /202107 | Periodic Safety Update EU Single assessment - osilodrostat                                                                                                                                                                                                                                                                                           | 10/02/2022 | n/a | PRAC Recommendation - maintenance |
| IA/0009             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                         | 25/10/2021 | n/a |                                   |
| PSUSA/10820 /202101 | Periodic Safety Update EU Single assessment - osilodrostat                                                                                                                                                                                                                                                                                           | 02/09/2021 | n/a | PRAC Recommendation - maintenance |
| IAIN/0007/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging | 05/05/2021 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10820 /202007   | Periodic Safety Update EU Single assessment - osilodrostat                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/02/2021   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IA/0005               | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                 | 25/01/2021   | n/a        |                        |                                     |
| IAIN/0002/G           | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - | 29/05/2020   | 04/06/2021 | Annex II and PL        |                                     |
| IA/0003               | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                               | 28/05/2020   | n/a        |                        |                                     |
| T/0001                | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 12/03/2020   | 01/04/2020 | SmPC, Labelling and PL |                                     |